Skip to main content
Fig. 4 | BMC Neurology

Fig. 4

From: FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide

Fig. 4

Kaplan–Meier curves for overall survival (OS) of different FXYD2 mRNA expression in 516 glioma patients with different WHO grades and different recurrent status in CGGA. The Kaplan–Meier curves for overall survival (A-D) of different FXYD2 mRNA expression in glioma patients with different WHO grades. The Kaplan–Meier curves for overall survival (E, F) of FXYD2 mRNA expression in patients with different recurrent gliomas. Log rank test was used to compare the difference between the two survival curves

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us